TumorGen MDx is Fighting the Root Cause of Cancer
Dr. Jeff Allen
President, CEO and Founder talks about the Vision of TumorGen
While tremendous strides continue developing new targeted therapies to fight the primary tumor, focus on the mechanisms of cancer metastasis remains challenging. New evidence is demonstrating late stage tumor metastasis may utilize different signaling pathways than the primary tumor. The CSC3™ System is capable of capturing and preserving circulating cancer cell clusters, thus providing a window into the different mechanisms of cancer metastasis.
Our system opens up new therapeutic target spaces and enables candidate drug validation in pre-clinical ex-vivo studies, de-risking future clinical trials.